• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer.

作者信息

Harada Kazuto, Abdelhakeem Ahmed A F, Ajani Jaffer A

机构信息

Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.

出版信息

Nat Rev Clin Oncol. 2019 Jan;16(1):9-10. doi: 10.1038/s41571-018-0108-x.

DOI:10.1038/s41571-018-0108-x
PMID:30291292
Abstract
摘要

相似文献

1
A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer.一种平衡行为：用于食管癌的双重免疫检查点抑制
Nat Rev Clin Oncol. 2019 Jan;16(1):9-10. doi: 10.1038/s41571-018-0108-x.
2
Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.免疫检查点抑制剂联合治疗致自身免疫性多发神经根炎 1 例：Ipilimumab 和 Nivolumab 联合治疗转移性黑色素瘤
J Clin Neurosci. 2020 Apr;74:240-241. doi: 10.1016/j.jocn.2020.01.055. Epub 2020 Jan 23.
3
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.在晚期黑色素瘤的靶向治疗中，影像学进展后 PD-1 免疫治疗的疗效。
Eur J Cancer. 2019 Jul;116:207-215. doi: 10.1016/j.ejca.2019.05.015. Epub 2019 Jun 15.
4
Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care.纳武利尤单抗联合伊匹单抗治疗转移性肾细胞癌的一线免疫治疗：一种新的治疗标准。
Cancer Biol Ther. 2019;20(1):6-7. doi: 10.1080/15384047.2018.1507260. Epub 2018 Oct 17.
5
Nivolumab plus ipilimumab in non-small-cell lung cancer.纳武利尤单抗联合伊匹单抗用于非小细胞肺癌。
Future Oncol. 2019 Jul;15(19):2287-2302. doi: 10.2217/fon-2019-0031. Epub 2019 May 8.
6
The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis.纳武利尤单抗联合伊匹单抗免疫治疗癌症的疗效和安全性：一项荟萃分析。
Immunopharmacol Immunotoxicol. 2021 Jun;43(3):386-394. doi: 10.1080/08923973.2021.1924195. Epub 2021 May 20.
7
Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.一名接受伊匹木单抗和纳武单抗检查点抑制剂免疫治疗的患者出现广泛的亚急性皮肤型红斑狼疮。
Dermatol Online J. 2019 Oct 15;25(10):13030/qt4md713j8.
8
Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.免疫检查点抑制剂癌症免疫疗法相关免疫介导反应的药物警戒评估。
Pharmacotherapy. 2017 Nov;37(11):1383-1390. doi: 10.1002/phar.2035. Epub 2017 Oct 26.
9
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会肾癌指南：纳武利尤单抗联合卡博替尼加入免疫检查点抑制联合治疗用于治疗初治转移性透明细胞肾细胞癌。
Eur Urol. 2021 Mar;79(3):339-342. doi: 10.1016/j.eururo.2020.12.005. Epub 2020 Dec 24.
10
Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌的成本效果分析。
JAMA Netw Open. 2021 May 3;4(5):e218787. doi: 10.1001/jamanetworkopen.2021.8787.

引用本文的文献

1
Immunotherapy use in oesophagogastric cancers-a review of the literature.免疫疗法在食管胃结合部癌症中的应用——文献综述。
Br J Cancer. 2022 Jul;127(1):21-29. doi: 10.1038/s41416-022-01751-4. Epub 2022 Mar 8.
2
An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7).一项研究者发起的2期研究：纳武利尤单抗联合低剂量伊匹木单抗作为微卫星高度不稳定的晚期胃癌或食管胃交界癌一线治疗方案（NO LIMIT，WJOG13320G/CA209 - 7W7）
Cancers (Basel). 2021 Feb 15;13(4):805. doi: 10.3390/cancers13040805.

本文引用的文献

1
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.微卫星不稳定性与林奇综合征泛癌的存在相关。
J Clin Oncol. 2019 Feb 1;37(4):286-295. doi: 10.1200/JCO.18.00283. Epub 2018 Oct 30.
2
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.FDA 批准概要：帕博利珠单抗用于表达 PD-L1 的复发性局部晚期或转移性胃或胃食管连接部腺癌。
Oncologist. 2019 Jan;24(1):103-109. doi: 10.1634/theoncologist.2018-0221. Epub 2018 Aug 17.